AI HealthTech Pioneer Biorce Opens U.S. Offices in Austin to Accelerate Global Expansion

Biorce expands its U.S. footprint and AI R&D operations by opening a new office in Austin, Texas. In Europe, Biorce is already rapidly transforming how Phase I–III clinical trials—up to market approval—are developed.

Austin, Texas, United States - [March 17, 2026] - AI healthtech pioneer Biorce is opening a second office in the United States this month in Austin, Texas, at the landmark address of 515 Congress Ave. The healthcare platform already has an office in New York.

The company was founded in Barcelona by a Portuguese founding team, with several members of the leadership team relocating to Texas. Biorce has received significant venture capital backing and has quickly risen to become one of the most prominent startups in Europe in Q1 2026. In January 2026, Biorce secured the largest Series A round ever raised in Spain or Portugal, totaling more than $52 million.

The new offices in Austin represent a strategic move to expand the company’s R&D team and build an AI healthtech hub in Texas. Austin is an attractive location for talent. Biorce is actively hiring and plans to continue growing its team of AI engineers as well as other departments.

“The expansion to Austin reflects our commitment to building a global center for AI-driven clinical trial innovation,” said Pedro Coelho, founder and CEO of Biorce. “We understand the challenges in global clinical development. Our platform brings together harmonized data, controlled input layers, and scalable AI models to solve some of the most complex problems in end to end clinical trials.” 

Earlier this month, the company received the prestigious 4YFN26 Award at the world’s largest, influential Mobile World Congress, recognizing its rapid growth and technological innovation. Biorce’s founding team emphasizes a science-first approach to AI innovation. “We are a mixture of true scientists and technologists building technology,” said Coelho. “That perspective shapes everything we build.”

About Biorce 

Biorce is a global healthtech startup, building defensible AI solutions for clinical trial development. Built on a foundation of 1 million clinical trials, 260,000+ protocols, and extensive scientific and regulatory datasets. The platform is aligned with leading governance standards, global legal frameworks and regulatory authorities. Biorce enables the design of smarter studies, reduces costly amendments, and accelerates timelines significantly.

Media contact

Lynn Caroline Broker

PR & Media collaborations

lynn.broeker [at] biorce [dot] com